Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Haematologica

Volumn 99, Issue 9, 2014, Pages 1441-1447

  Hanfstein, Benjamin ^a   Lauseker, Michael ^b   Hehlmann, Rüdiger ^a   Saussele, Susanne ^a   Erben, Philipp ^a   Dietz, Christian ^a   Fabarius, Alice ^a   Proetel, Ulrike ^a   Schnittger, Susanne ^c   Haferlach, Claudia ^c   Krause, Stefan W ^d   Schubert, Jörg ^e   Einsele, Hermann ^f   Hänel, Mathias ^g   Dengler, Jolanta ^h   Falge, Christiane ⁱ   Kanz, Lothar ^j   Neubauer, Andreas ^k   Kneba, Michael ^l   Stegelmann, Frank ^m   Pfreundschuh, Michael ⁿ   Waller, Cornelius F ^o   Spiekermann, Karsten ^b   Baerlocher, Gabriela M ^p   Pfirrmann, Markus ^b   Hasford, Joerg ^b   Hofmann, Wolf Karsten ^a   Hochhaus, Andreas ^q   Müller, Martin C ^a   more..

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^e Evangelisches Krankenhaus Hamm   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g KLINIKUM CHEMNITZ   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

ⁱ KLINIKUM NÜRNBERG   (Germany)

^j UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^k UNIVERSITY HOSPITAL MARBURG   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ SAARLAND UNIVERSITY   (Germany)

^o UNIVERSITY OF FREIBURG   (Germany)

^p UNIVERSITY OF BERN   (Switzerland)

^q JENA UNIVERSITY HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; MESSENGER RNA; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BCR ABL 1 FUSION GENE; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG TOLERANCE; FEMALE; FUSION GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLEX POLYMERASE CHAIN REACTION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; THROMBOCYTE COUNT; TREATMENT RESPONSE; ADOLESCENT; AGED; ALTERNATIVE RNA SPLICING; CONTROLLED STUDY; DRUG EFFECTS; DRUG MONITORING; GENETICS; GENOTYPE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REMISSION; THROMBOCYTE; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; BENZAMIDES; BLOOD PLATELETS; DRUG MONITORING; FEMALE; FUSION PROTEINS, BCR-ABL; GENOTYPE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKOCYTES; MALE; MIDDLE AGED; PHENOTYPE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84907371261     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.096537     Document Type: Article

References (28)

1. Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451-64.
2. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343-56.
3. Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986;47(2):277-84.
4. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on throm-bopoiesis in chronic myeloid leukaemia. Eur J Cancer. 2000;36(11):1395-401.
5. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001;98(10):2887-93.
6. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88(7):2375-84.
7. Melo JV. BCR-ABL gene variants. Baillieres Clin Haematol. 1997;10(2):203-22.
8. Polampalli S, Choughule A, Negi N, Shinde S, Baisane C, Amre P, et al. Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Genet Mol Res. 2008;7(4):1138-49.
9. Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N, et al. Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-{alpha} in Newly Diagnosed Chronic Myeloid Leukemia. J Clin Oncol. 2011;29(12):1634-42.
10. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-51.
11. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6): 1809-20.
12. Cross NC, White HE, Muller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172-5.
13. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive poly-merase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82(6): 1929-36.
14. Cross NC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22(3): 355-65.
15. Muller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23(11):1957-63.
16. Pfirrmann M, Hochhaus A, Lauseker M, Saussele S, Hehlmann R, Hasford J. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25(09): 1433-8.
17. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood. 1991;78(5):1155-61.
18. Tefferi A, Bren GD, Wagner KV, Schaid DJ, Ash RC, Thibodeau SN. The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia. Leukemia. 1990;4(12):839-42.
19. Jaubert J, Martiat P, Dowding C, Ifrah N, Goldman JM. The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia. Br J Haematol. 1990;74(1):30-5.
20. Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991;78(12):3125-7.
21. Opalka B, Wandl UB, Stutenkemper R, Kloke O, Seeber S, Niederle N. No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood. 1992;80(7): 1854-5.
22. Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 1995;89(3):546-54.
23. Castagnetti F, Gugliotta G, Palandri F, Breccia M, Specchia G, Abruzzese E, et al. BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis. ASH Annual Meeting Abstracts. 2010;116(21):1230.
24. Vega-Ruiz A, Kantarjian H, Shan J, Wierda W, Burger J, Verstovsek S, et al. Better Molecular Response to Imatinib for Patients (pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Carrying the b3a2 Transcript Compared to b2a2. ASH Annual Meeting Abstracts. 2007;110(11): 1939.
25. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse tran-scriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12): 2318-57.
26. Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94(10):1362-7.
27. de Lemos JA, de Oliveira CM, Scerni AC, Bentes AQ, Beltrao AC, Bentes IR, et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res. 2005;4(4):803-11.
28. Sharma P, Kumar L, Mohanty S, Bose S, Kochupillai V. Does BCR-ABL transcript type predict cytogenetic response to ima-tinib mesylate in chronic phase, chronic myeloid leukemia patients? J Clin Oncol. 2007;7043.